ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/radiopharmaceutics
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/radiopharmaceutics
14
trial(s) found.
NCT06909825
Advanced
Phase 2
Recruiting
A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) (
FPI-2265-203
)
PARP inhibitor
radioligand,PSMA-targeting
+ radiopharmaceutics
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4509 - North Lakes - Icon Cancer Centre North Lakes
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06879041
Advanced
Phase 1
Recruiting
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (
D7580C00001
)
radioligand,PSMA-targeting
+ radiopharmaceutics
Castrate-resistant prostate cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06184035
Radonc
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, Dose Escalation and Dose Expansion, First-in-human, Open-label, Multicenter, Single-arm Study Evaluating the Safety, Tolerability, Dosimetry, and Early Efficacy of [177Lu]Lu-SN201 in Participants With Progressive or Treatment-refractory Locally Advanced Unresectable, Metastatic or Recurrent Solid Tumors (
Tumorad
)
177Lu-SN201
cancer therapy
nanoparticle radiopharmaceutics
radiopharmaceutics
+ nanoparticle radiopharmaceutics
Cancer
Solid tumour
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05983198
Radonc
Phase 1 / Phase 2
Recruiting
SatisfACtion
: Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With mHSPC and Heavily Pre-treated PSMA-positive mCRPC, With/Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy
radioligand,PSMA-targeting
+ radiopharmaceutics
Prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT05868174
Radonc
Phase 1
Recruiting
A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors (
177Lu-TLX250-001
)
177Lu-anti-CA9-radioconjugate
DNA-dependent protein kinase inhibitor
+ radiopharmaceutics
Clear cell renal cell carcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05720130
Radonc
Phase 1 / Phase 2
Recruiting
Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study). (
TheraPb-ADVC001
)
radioligand,PSMA-targeting
+ radiopharmaceutics
Castrate-resistant prostate cancer
Prostate cancer
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
NCT04876651
Radonc
Phase 3
Recruiting
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug (
177Lu-TLX591-002
)
radioligand,PSMA-targeting
+ radiopharmaceutics
Prostate cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04597411
Radonc
Phase 1
Recruiting
AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy (
PSMA-617-100
)
radioligand,PSMA-targeting
+ radiopharmaceutics
Castrate-resistant prostate cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
NCT03746431
Radonc
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours (
FPX-01-01
)
FPI-1175
FPI-1547
IGF1R-radionucleotide conjugate
cancer therapy
radioconjugate therapy
radiopharmaceutics
+ radiopharmaceutics
Breast cancer
Carcinoma
Cervical cancer
Endometrial cancer
HER2-negative breast cancer
Head and neck squamous cell carcinoma
Ovarian cancer
Solid tumour
Triple-negative breast cancer
Uveal melanoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
ACTRN12623000216617
Radonc
Phase 1
Not yet recruiting
A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands (
RESCUE
)
radioligand,PSMA-targeting
+ radiopharmaceutics
Prostate cancer
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12623000185662
Radonc
Phase 1
Recruiting
A multicentre, open-label, Phase I study investigating the safety, tolerability, and efficacy of 177Lu-SSO110 with 68Ga-SSO120 companion imaging in participants with extensive stage small cell lung cancer (ES-SCLC) who are on maintenance treatment with immune checkpoint inhibition (The LuSato1 Study). (
SSO110-01
)
177Lu-DOTA-radioconjugate
+ radiopharmaceutics
Small-cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12622001378718
Radonc
Phase 1 / Phase 2
Recruiting
Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma (TheraPb – Phase I/II) (
TheraPb-phase-I-II
)
radioligand,PSMA-targeting
+ radiopharmaceutics
Prostate cancer
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12621000802808
Advanced
Phase 2
Recruiting
A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults. (
LU-TEMP
)
alkylating agent
+ radiopharmaceutics
Cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
NCT05450744
Advanced
Phase 1
Unknown
A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients With Newly Diagnosed Glioblastoma (
IPAX-2
)
131I-IPA
131I-TLX-101
cancer therapy
cancer therapy,LAT1-targeting
cancer therapy,LAT2-targeting
radioiodine conjugate
radioiodine therapy
radioligand,LAT1/LAT2-targeting
radiopharmaceutics
+ radiopharmaceutics
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (12)
Not yet recruiting (1)
Unknown (1)
Recruitment Country and State
VIC (9)
NSW (7)
QLD (7)
SA (5)
WA (3)
NZ (3)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (5)
Phase 2 (2)
Phase 3 (1)
Trial Type
Radonc (10)
Advanced (4)
Cancer Therapy Class
PSMA
57%
AR
14%
androgen axis
14%
PARP
7%
DNA-dependent protein kinase
7%
CYP17A1
7%
LAT1
7%
LAT2
7%
Facility
4102 - Woolloongabba - Princess Alexandra Hospital (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
6150 - Murdoch - Fiona Stanley Hospital (3)
2109 - North Ryde - Macquarie University Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
3168 - Clayton - Monash Medical Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
4509 - North Lakes - Icon Cancer Centre North Lakes (1)
3002 - East Melbourne - Epworth Freemasons (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3004 - Melbourne, Southbank - Alfred Health (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre (1)
Cancer Type
Cancer
Solid tumour
Urogenital cancer
Male genital cancers
Prostate cancer
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Carcinoma
Clear cell renal cell carcinoma
Kidney cancer
Breast adenocarcinoma
Breast cancer
Cervical cancer
Endometrial cancer
Gynaecological cancer
HER2-negative breast cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Melanoma
Ovarian cancer
Triple-negative breast cancer
Uveal melanoma
Viral-related cancer
Lung cancer
Neuroendocrine carcinoma
Respiratory tract cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Thoracic cancer
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy